Free Trial

Mersana Therapeutics (MRSN) Stock Forecast & Price Target

Mersana Therapeutics logo
$1.81
-0.06 (-3.21%)
(As of 10/31/2024 ET)

Mersana Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
6

Based on 8 Wall Street analysts who have issued ratings for Mersana Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MRSN.

Consensus Price Target

$6.00
231.49% Upside
According to the 8 analysts' twelve-month price targets for Mersana Therapeutics, the average price target is $6.00. The highest price target for MRSN is $9.00, while the lowest price target for MRSN is $3.00. The average price target represents a forecasted upside of 231.49% from the current price of $1.81.
Get the Latest News and Ratings for MRSN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mersana Therapeutics and its competitors.

Sign Up

MRSN Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
0 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$6.00$6.00$6.29$8.57
Forecasted Upside231.49% Upside227.87% Upside290.42% Upside611.32% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Reduce

MRSN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Mersana Therapeutics Stock vs. The Competition

TypeMersana TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside220.86% Upside15,724.54% Upside9.23% Upside
News Sentiment Rating
Neutral News

See Recent MRSN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/27/2024Citigroup
3 of 5 stars
 Lower TargetBuy ➝ Buy$6.00 ➝ $5.00+217.46%
8/14/2024Robert W. Baird
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$4.00 ➝ $3.00+122.22%
7/29/2024Lifesci Capital
2 of 5 stars
C. Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/19/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral$5.00+2.88%
2/29/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$9.00+85.57%
2/29/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$6.00+23.71%
2/29/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$7.00+44.33%
2/29/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$2.00 ➝ $7.00+44.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:12 PM ET.


MRSN Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Mersana Therapeutics is $6.00, with a high forecast of $9.00 and a low forecast of $3.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRSN shares.

According to analysts, Mersana Therapeutics's stock has a predicted upside of 231.49% based on their 12-month stock forecasts.

Mersana Therapeutics has been rated by research analysts at Citigroup, and Robert W. Baird in the past 90 days.

Analysts like Mersana Therapeutics more than other "medical" companies. The consensus rating score for Mersana Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.79. Learn more on how MRSN compares to other companies.


This page (NASDAQ:MRSN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners